Figure 5 | Scientific Reports

Figure 5

From: Clinical, pathophysiologic, and genomic analysis of the outcomes of primary head and neck malignancy after pulmonary metastasectomy

Figure 5

In vitro validation of ALDH7A1 mutation. (a) Sanger sequencing showed that the point mutation (ALDH7A1, missense mutation, c.1168 G > C, rs121912707) was compatible with the results from the high-throughput sequencing (WES). (b) Expression level of ALDH7A1 demonstrated by immunohistochemistry (IHC) staining was lower for short-term PMS HNSCC (ALDH7A1, missense mutation) than for long-term PMS HNSCC (ALDH7A1, wild-type). (c) Ki-67 stain of short-term PMS HNSCC was higher than that of ACC (85% vs. 1%) (d) After transfecting ALDH7A1 siRNA in Cal27 and HSC2 cells, the expression of ALDH7A1 was knockdown compared to the expression in the control groups, but cell viability increased. (e,g) In BrDU assay, knocking down ALDH7A1 significantly increased the number of synthesized DNA in replicating cell. (f,h) In EB/AO assay, apoptotic cells of Cal27 were also decreased after adding siALDH7A1.

Back to article page